Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $38.59 Average Target Price from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned an average recommendation of “Moderate Buy” from the nineteen research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, thirteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $38.4706.

Several equities analysts recently issued reports on DYN shares. Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Tuesday, December 9th. Raymond James Financial restated a “strong-buy” rating and issued a $40.00 price target on shares of Dyne Therapeutics in a report on Monday, December 8th. Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, December 9th. Morgan Stanley upped their price target on Dyne Therapeutics from $46.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Finally, Oppenheimer upgraded Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $11.00 to $40.00 in a report on Wednesday, December 10th.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $19.85 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $26.22. The firm has a market cap of $2.83 billion, a PE ratio of -5.42 and a beta of 1.30. The firm’s fifty day moving average is $19.70 and its 200-day moving average is $14.54.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. Sell-side analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of DYN. Chung Wu Investment Group LLC purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at about $30,000. CWM LLC grew its holdings in shares of Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after acquiring an additional 1,900 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Dyne Therapeutics by 378.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after acquiring an additional 2,446 shares during the last quarter. Quarry LP purchased a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $47,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.